Tazverik (tazemetostat tablets – Epizyme) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has relapsed or refractory disease
• Patient meets ONE of the following: (i) Patient has tried at least two prior systemic therapies OR (ii) According to the prescriber, there are no appropriate alternative therapies

Approval duration

1 year